Separate Registration: Please, access the Registration Area to apply and pay. Or click on the “SUBSCRIBE” button below.


Free of charge to HEMO attendees (until 2 events)
Proceed with your registration at the event website.
Access the registered area to select the event and secure your registration in advance.


II Clinical Research Course (CRTI Support)

Ângelo Maiolino
Eduardo Magalhães Rego

I Joint Symposium of Update on Hemostasis and Thrombosis

Dayse Lourenço
Erich Vinicius de Paula
Murilo Rossi

Brazilian Society of Cardiology
Brazilian Society of Angiology and Vascular Surgery

Course description: This symposium will address hemostasis and thrombosis issues in the intersection areas of the Hematologist, Cardiologist, Vascular Surgeon and General Practitioner, with emphasis on the diagnosis and management of venous and arterial thromboembolic events. Although they represent the leading cause of adult mortality in many countries, the approach to these conditions is grouped in different disciplines. The rise of new diagnostic and therapeutic tools has led to a significant increase in scientific knowledge in the area, thus challenging the professionals who work with these patients, particularly when the clinical presentations do not respect the artificial limits of hematology, cardiology, vascular surgery and the internal medicine. It is expected that the presence of professionals from these four areas, both as speakers and at the audience, might allow a deepening of these discussions.

Provisional format: presentations should be built upon clinical scenario illustrating prevalent and relevant issues for the practice of these four disciplines. Relevant subjects will be chosen to allow the joint discussion of clinical problems. Both periods of the day can be used to discuss conditions more related to venous thromboembolism (hematology / vascular surgery / internal medicine) in the morning, and topics related to arterial thromboses and antithrombotic drug management in the afternoon.

Event Scheduling

08:30 – 10:00: Tromboembolismo venoso: diagnóstico, fatores de risco, profilaxia

08:30 – 08:40: Opening
Speakers: Rossi Murilo da Silva e Erich Vinicius de Paula

08:40 – 09:00: Associação entre TEV e doença arterial oclusiva: o que há na literatura
Speaker: Fernanda Orsi

09:00 – 09:20: Estratificação do risco de recorrência do TEV
Speaker: Daniel Dias Ribeiro

09:20 – 09:40: A resposta inflamatória na trombose venosa profunda
Speaker: Adilson Paschoa

09:40 – 10:00: Discussion

10:00 – 10:30: Break

10:30 – 12:00: Tromboembolismo venoso: manejo
Moderators: Roberto Sacilotto e Dayse Maria Lourenço

10:30 – 10:50: Uso de DOACs em pediatria
Speaker: Soraia Rouxinol

10:50 – 11:10: Anticoagulação na gestação
Speaker: André Luiz Malavasi

11:10 – 11:30: Anticoagulações nas tromboses em sítios pouco usuais
Speaker: Marcos Areias

11:30 – 12:00: Discussion

12:00 – 13:30: Pause for lunch

13:30 – 15:00: Terapia antitrombótica: anticoagulação oral
Moderators: João Carlos de Campos Guerra e Carlos Gun

13:30 – 13:50: Anticoagulação oral na FA: conduta em pacientes especiais
Speaker: Carlos Gun

13:50 – 14:10: Anticoagulação oral nas valvopatias: conduta em situações especiais
Speaker: Dalmo Antonio Ribeiro Moreira

14:10 – 14:30: O papel da anticoagulação oral nas doenças aterotrombóticas na era dos DOACs
Speaker: Antonio Eduardo Pereira Pesaro

14:30 – 15:00: Discussion

15:00 – 15:30: Break

15:30 – 17:00: Situações especiais
Moderators: Daniel Dias Ribeiro e Otávio Rizzi Coelho

15:30 – 15:50: Variações de doses nos estudos clínicos com DOACs: como traduzir para a prática clínica?
Speaker: Dayse Maria Lourenço

15:50 – 16:10: Novos antiagregantes plaquetários: impacto na prática clínica
Speaker: Otávio Rizzi Coelho

16:10 – 16:30: AVC criptogênico: investigação e manejo
Speaker: Gisele Sampaio

16:30 – 17:00: Discussion

Update on Laboratory Hemotherapy

Alfredo Mendrone Jr.
Eugenia Maria Amorim Ubiali
Nanci Alves Salles

08:30 – 09:00: Quality management in Hemotherapy laboratories
Speaker: Ana Paula Rocha Diniz Zanelli

09:00 – 10:30: Round-table: Donors and recipients immunohematology
Moderator: to define

09:00 – 09:20: Anti-D sera selection criteria for donors and recipients RhD typing
Speaker: Lilian Castilho

09:20 – 09:40: Hemolysins or agglutinins screening in blood donors?
Speaker: Shirley Castilho

09:40 – 10:00: Management of difficult cases in multiple antibodies association
Speaker: Carla Luana Dinardo

10:00 – 10:20: Management of difficult cases in autoimmune hemolytic anemia
Speaker: Melca Barros

10:20 – 10:30: Discussion

10:30 – 11:00: Break

11:00 – 12:30: Round-table: Laboratory tests for blood-borne diseases
Moderator: to define

11:00 – 11:20: Internal Quality Control for Serology and Nat laboratories
Speaker: Márcia Otani

11:20 – 11:40: Internal Quality Control: daily and regular analysis
Speaker: Vanderleia B. Valente

11:40 – 12:00: Samples transport validation: a practical approach
Speaker: Milena B. de Oliveira

12:00 – 12:20: Ministry of Health data on external quality control of molecular and serological tests
Speaker: Priscila Murador

12:20 – 12:30: Discussion

12:30 – 14:00: Break

14:00 – 14:30: Processes validation in Hemotherapy services
Moderator: Ana Paula Rocha Diniz Zanelli

14:30 – 16:00: Round-table: Processing and quality control of blood components
Moderator: to define

14:30 – 14:50: Quality in the routine of blood components production and modification
Speaker: Edson Lara Moreto

14:50 – 15:10: Blood components storage management
Speaker: Flávia Givisiez

15:10 – 15:30: Pathogens inactivation: methods, advantages and troubles
Speaker: to define

15:30 – 15:50: Blood components quality control: sampling x reliability
Speaker: Patrícia Sierra

15:50 – 16:00: Discussion

16:00 – 16:30: Break

16:30 – 18:00: Round-table: Hemotherapy laboratories automation
Moderator: to define

16:30 – 16:50: What have we learned and improved with the serology automation
Speaker: Ana Claudia de Matos Azevedo Furlanetto

16:50 – 17:10: Automation options in donors and pre-transfusion immunohematology
Speaker: Vivian Scigliano

17:10 – 17:30: Automation of molecular tests for transfusion-transmitted diseases
Speaker: José Eduardo Levi

17:30 – 17:50: Validation of equipment, software and interfacing systems
Speaker: Nanci Salles

17:50 – 18:00: Discussion

Latin American MDS Foundation Symposium

Separate Registration

Please, access the Registration Area to apply and pay.

We are proud to announce that on October 31st, 2018, the Myelodysplastic Syndromes (MDS) Foundation will organize its first meeting in Brazil during the Annual Congress of the Brazilian Association of Hematology and Cell Therapy: Latin American MDS Foundation Symposium.

The definition of the genetic basis of myelodysplastic syndrome has opened avenues of research and there have been remarkable advances in the last few years. Well-known experts in the field will cover different topics that span from inherited predisposition to developing myeloid malignancies to age-related clonal hematopoiesis and its clinical implications. Case-based discussions will help participants understand the clinical-decision making processes regarding diagnosis, prognostication and treatment of myelodysplastic syndromes and related disorders.

Silvia M. M. Magalhães & Mario Cazzola

AABB / ABHH Accreditation Program Audit Training:

Separate congressional registrations
Please contact this site to sign up and make the payment.

DATE / TIME / VENUE: 31/10/18 from 9:00 a.m. to 5:00 p.m. at the Transamerica Expo Center.

PURPOSE: spread the full knowledge about the use of the ABHH/AABB standards,
related to the quality management system and auditing techniques.

SPECIALISTS:  ABHH consultants will present necessary steps for planning, preparing,
executing and evaluating internal and external audits.

REQUIREMENTS: The AABB/ABHH Auditors training is directed to health professionals
working in Blood Banks. Whoever takes part in the training is not automatically able to
be an assessor. To become an assessor of the hemotherapy program the applicant
must have 10 years of proven experience in hemotherapy (technical area) and 5 years
of proven experience in quality management. For cell therapy aplicants should have 5
years of proven experience in cell therapy (technical area) and 5 years of proven
experience in quality management.